KR102733714B1 - 세포 집단의 증대를 위한 방법 및 조성물 - Google Patents

세포 집단의 증대를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102733714B1
KR102733714B1 KR1020207013360A KR20207013360A KR102733714B1 KR 102733714 B1 KR102733714 B1 KR 102733714B1 KR 1020207013360 A KR1020207013360 A KR 1020207013360A KR 20207013360 A KR20207013360 A KR 20207013360A KR 102733714 B1 KR102733714 B1 KR 102733714B1
Authority
KR
South Korea
Prior art keywords
delete delete
hsa
mir
cells
ythdf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013360A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078536A (ko
Inventor
전뤼 리
펑쉬 첸
린헝 리
촨 허
Original Assignee
스토워스 인스티튜트 포 메디컬 리서치
유니버시티 오브 시카고
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스토워스 인스티튜트 포 메디컬 리서치, 유니버시티 오브 시카고 filed Critical 스토워스 인스티튜트 포 메디컬 리서치
Publication of KR20200078536A publication Critical patent/KR20200078536A/ko
Application granted granted Critical
Publication of KR102733714B1 publication Critical patent/KR102733714B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
KR1020207013360A 2017-10-09 2018-10-09 세포 집단의 증대를 위한 방법 및 조성물 Active KR102733714B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762570076P 2017-10-09 2017-10-09
US62/570,076 2017-10-09
US201862695820P 2018-07-09 2018-07-09
US62/695,820 2018-07-09
PCT/US2018/055092 WO2019074980A1 (en) 2017-10-09 2018-10-09 METHODS AND COMPOSITIONS FOR EXPANSION OF CELL POPULATION

Publications (2)

Publication Number Publication Date
KR20200078536A KR20200078536A (ko) 2020-07-01
KR102733714B1 true KR102733714B1 (ko) 2024-11-26

Family

ID=66101161

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013360A Active KR102733714B1 (ko) 2017-10-09 2018-10-09 세포 집단의 증대를 위한 방법 및 조성물

Country Status (6)

Country Link
US (1) US12359200B2 (enExample)
EP (1) EP3694533A4 (enExample)
JP (2) JP2020536554A (enExample)
KR (1) KR102733714B1 (enExample)
CN (2) CN120366217A (enExample)
WO (1) WO2019074980A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046969B2 (en) 2017-05-24 2021-06-29 Epiplanta Biotech Ltd. Transgenic plant and the method for producing the same
CN120366217A (zh) 2017-10-09 2025-07-25 斯托瓦斯医学研究所 用于扩增细胞群的方法和组合物
US20230018989A1 (en) * 2019-07-03 2023-01-19 Children's Medical Center Corporation Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis
CA3180620A1 (en) * 2020-06-09 2021-12-16 Meng Xu Compositions and methods for enhancing immune response
CN116261459A (zh) * 2020-07-09 2023-06-13 中国科学院上海药物研究所 用于抑制ythdf1的组合物和方法
EP4185305A4 (en) * 2020-09-09 2024-08-28 Duke University METHODS OF REPROGRAMMING TARGET CELLS
WO2022086935A1 (en) * 2020-10-19 2022-04-28 The General Hospital Corporation Targeting xist and rna methylation for x reactivation therapy
CN112941102A (zh) * 2021-01-26 2021-06-11 南方医科大学 一种子痫前期小鼠动物模型的构建方法及其应用
CN112941105A (zh) * 2021-02-08 2021-06-11 江西农业大学 一种m6A“阅读器”YTHDF2基因改造方法及其应用
CN112899238B (zh) * 2021-04-01 2023-09-26 中国药科大学 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用
WO2022241165A2 (en) * 2021-05-12 2022-11-17 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for mutated hotair in the treatment of cancers
CN116024326A (zh) * 2022-09-21 2023-04-28 安徽中医药大学第一附属医院(安徽省中医院) 类风湿关节炎m6A甲基化修饰基因PTEN的应用及其检测方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN120513295A (zh) * 2023-01-09 2025-08-19 韩国生命工学研究院 Fto基因表达受到抑制的干细胞和由其分化的免疫细胞
WO2024201420A1 (en) * 2023-03-31 2024-10-03 Biorchestra Co., Ltd. Mirna-484 inhibitors and uses thereof
WO2025117708A2 (en) * 2023-11-28 2025-06-05 Baruch S. Blumberg Institute Method and system for use of mutant mrna in liquid biopsies to risk stratify and manage cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027376A2 (en) 2010-08-23 2012-03-01 The Research Foundation Of State University Of New York Method for expansion of stem cells and the use of such cells
US20160264934A1 (en) * 2015-03-11 2016-09-15 The General Hospital Corporation METHODS FOR MODULATING AND ASSAYING m6A IN STEM CELL POPULATIONS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US7018801B2 (en) 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
US20070065447A1 (en) 2003-10-29 2007-03-22 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US8263403B2 (en) * 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
ES2672693T3 (es) 2011-04-20 2018-06-15 The Regents Of The University Of California Método para el acondicionamiento y quimioselección combinadas en un único ciclo
CN107207557B (zh) * 2015-01-26 2020-07-10 中国科学院动物研究所 miRNA对m6A修饰水平的调控方法及其应用
CN120366217A (zh) 2017-10-09 2025-07-25 斯托瓦斯医学研究所 用于扩增细胞群的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027376A2 (en) 2010-08-23 2012-03-01 The Research Foundation Of State University Of New York Method for expansion of stem cells and the use of such cells
US20160264934A1 (en) * 2015-03-11 2016-09-15 The General Hospital Corporation METHODS FOR MODULATING AND ASSAYING m6A IN STEM CELL POPULATIONS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell Stem Cell. Vol.13, 520-533(2013)
NATURE. VOL 549, 273-276(2017.09.)
Nucleic Acids Research. Vol. 41, No. 21, 9753-9763(2013)

Also Published As

Publication number Publication date
KR20200078536A (ko) 2020-07-01
US20200370044A1 (en) 2020-11-26
US12359200B2 (en) 2025-07-15
EP3694533A1 (en) 2020-08-19
CN120366217A (zh) 2025-07-25
JP2023171952A (ja) 2023-12-05
WO2019074980A1 (en) 2019-04-18
CN111511376B (zh) 2025-02-25
EP3694533A4 (en) 2021-07-14
JP2020536554A (ja) 2020-12-17
CN111511376A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
KR102733714B1 (ko) 세포 집단의 증대를 위한 방법 및 조성물
JP6491661B2 (ja) 幹細胞微粒子及びｍｉＲＮＡ
US10787643B2 (en) Methods, kits, and compositions for stem cell self-renewal
JP2020536554A5 (enExample)
US20210161967A1 (en) Extracellular vesicles and uses thereof
EP3259344A1 (en) Generating arterial endothelial cell populations
Li et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
US9896659B2 (en) Methods, kits, and compositions for stem cell self-renewal
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
US20130309209A1 (en) Formation of hematopoietic progenitor cells from mesenchymal stem cells
Chan et al. R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling
US12319928B2 (en) Methods of treating Danon disease
HK40031696B (zh) 用於扩增细胞群的方法和组合物
HK40031696A (en) Methods and compositions for expansion of cell population
Xu et al. Enhance the therapeutic efficacy of human umbilical cord-derived mesenchymal stem cells in prevention of acute graft-versus-host disease through CRISPLD2 modulation
CN102131929A (zh) 一种内源性短发夹rna及其用途
US20150283164A1 (en) Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2
Alves et al. Generation of Phd2-haplodeficient macrophages with proresolution effects for the treatment of limb ischemia
Chen The role of splicing and microenvironmental aberrancies as drivers of disease in myelodysplastic neoplasms
Zhong The role of the homeobox transcription factor Duxbl in rhabdomyosarcoma formation
Truong Identifying novel genetic targets that regulate azacitidine sensitivity in myelodysplastic syndromes
Paris Novel regulators of cancer stem cell biology in acute myeloid leukaemia
Kandell Investigating Mechanisms of Immune Suppression Secondary to an Inflammatory Microenvironment
Frobel DNA methylation changes in hematopoietic development and iPSC-derived model systems
Kowalski The role of Sdf-1 in the migration and differentiation of stem cells during skeletal muscle regeneration.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240828

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241120

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241121

End annual number: 3

Start annual number: 1

PG1601 Publication of registration